Literature DB >> 18780293

Prolonged androgen receptor loading onto chromatin and the efficient recruitment of p160 coactivators contribute to androgen-independent growth of prostate cancer cells.

Xu-Bao Shi1, Lingru Xue, June X Zou, Regina Gandour-Edwards, Hongwu Chen, Ralph W deVere White.   

Abstract

BACKGROUND: Growth of most ablation-resistant prostate cancers (CaPs) is dependent on androgen receptor (AR) activity in chromatin, but cancer cells in these tumors have acquired altered AR activation. It is unclear how the aberrantly activated AR loads onto regulatory regions of AR-targeted genes. The purpose of this study was to assess the AR chromatin loading in an androgen-depleted environment.
METHODS: The expression of PSA in androgen-resistant CaP cells was determined using RT-PCR and Western blot analysis. In order to investigate the binding of the AR to the PSA gene regulatory regions, chromatin immunoprecipitation (ChIP) was performed in the androgen-independent cds2 cell line in the presence or absence of androgens. In addition, we examined the involvement of p160 coactivators in the chromatin loading of the AR.
RESULTS: It was found that constitutive activation of PSA expression was the result of sustained occupancy by the AR at the regulatory region of this gene. This stable AR loading was not blocked by the AR antagonist bicalutamide. Furthermore, androgen-resistant CaP cells highly expressed both AR and the p160 coactivators and the AR was able to recruit TIF2. Downregulation of TIF2 using short hairpin RNA disrupted the AR loading to the PSA enhancer and subsequently inhibited AR activity.
CONCLUSION: Prolonged AR localization to the regulatory regions of AR targeted genes and the recruitment of p160 coactivators are a potential mechanism leading to androgen-independent activation of the AR. Disruption of AR chromatin loading could therefore become an important therapeutic target for this disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18780293     DOI: 10.1002/pros.20849

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  10 in total

Review 1.  Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer.

Authors:  E S Antonarakis; A J Armstrong
Journal:  Prostate Cancer Prostatic Dis       Date:  2011-05-17       Impact factor: 5.554

2.  Reconfiguring the AR-TIF2 Protein-Protein Interaction HCS Assay in Prostate Cancer Cells and Characterizing the Hits from a LOPAC Screen.

Authors:  Ashley T Fancher; Yun Hua; Daniel P Camarco; David A Close; Christopher J Strock; Paul A Johnston
Journal:  Assay Drug Dev Technol       Date:  2016-09-08       Impact factor: 1.738

3.  High-content positional biosensor screening assay for compounds to prevent or disrupt androgen receptor and transcriptional intermediary factor 2 protein-protein interactions.

Authors:  Yun Hua; Tong Ying Shun; Christopher J Strock; Paul A Johnston
Journal:  Assay Drug Dev Technol       Date:  2014-09       Impact factor: 1.738

4.  Loss of exogenous androgen dependence by prostate tumor cells is associated with elevated glucuronidation potential.

Authors:  Brenna M Zimmer; Michelle E Howell; Qin Wei; Linlin Ma; Trevor Romsdahl; Eileen G Loughman; Jonathan E Markham; Javier Seravalli; Joseph J Barycki; Melanie A Simpson
Journal:  Horm Cancer       Date:  2016-06-15       Impact factor: 3.869

5.  Cyclin D1 is a selective modifier of androgen-dependent signaling and androgen receptor function.

Authors:  Clay E S Comstock; Michael A Augello; Matthew J Schiewer; Jason Karch; Craig J Burd; Adam Ertel; Erik S Knudsen; Walter J Jessen; Bruce J Aronow; Karen E Knudsen
Journal:  J Biol Chem       Date:  2011-01-05       Impact factor: 5.157

6.  Role of androgen receptor and associated lysine-demethylase coregulators, LSD1 and JMJD2A, in localized and advanced human bladder cancer.

Authors:  Eric C Kauffman; Brian D Robinson; Martin J Downes; Leagh G Powell; Ming Ming Lee; Douglas S Scherr; Lorraine J Gudas; Nigel P Mongan
Journal:  Mol Carcinog       Date:  2011-03-11       Impact factor: 4.784

7.  Peroxisome proliferator-activated receptor gamma coactivator-1alpha interacts with the androgen receptor (AR) and promotes prostate cancer cell growth by activating the AR.

Authors:  Masaki Shiota; Akira Yokomizo; Yasuhiro Tada; Junichi Inokuchi; Katsunori Tatsugami; Kentaro Kuroiwa; Takeshi Uchiumi; Naohiro Fujimoto; Narihito Seki; Seiji Naito
Journal:  Mol Endocrinol       Date:  2009-11-02

8.  Assays to Interrogate the Ability of Compounds to Inhibit the AF-2 or AF-1 Transactivation Domains of the Androgen Receptor.

Authors:  Ashley T Fancher; Yun Hua; Christopher J Strock; Paul A Johnston
Journal:  Assay Drug Dev Technol       Date:  2019-09-06       Impact factor: 1.738

9.  High-Content Screening Campaign to Identify Compounds That Inhibit or Disrupt Androgen Receptor-Transcriptional Intermediary Factor 2 Protein-Protein Interactions for the Treatment of Prostate Cancer.

Authors:  Ashley T Fancher; Yun Hua; Daniel P Camarco; David A Close; Christopher J Strock; Paul A Johnston
Journal:  Assay Drug Dev Technol       Date:  2018-08-15       Impact factor: 1.738

10.  Reciprocal feedback inhibition of the androgen receptor and PI3K as a novel therapy for castrate-sensitive and -resistant prostate cancer.

Authors:  Wenqing Qi; Carla Morales; Laurence S Cooke; Benny Johnson; Bradley Somer; Daruka Mahadevan
Journal:  Oncotarget       Date:  2015-12-08
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.